A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT04039607. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Study identification
- NCT ID
- NCT04039607
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 732 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2019
- Primary completion
- Jul 8, 2026
- Completion
- Jul 8, 2026
- Last update posted
- Aug 24, 2026
2019 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0292 | Tucson | Arizona | 85719 | — |
| Local Institution - 0288 | Coronado | California | 92118 | — |
| Local Institution - 0157 | Duarte | California | 91010-3012 | — |
| Local Institution - 0077 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0027 | Louisville | Kentucky | 40217 | — |
| Local Institution - 0190 | Baltimore | Maryland | 21287 | — |
| Local Institution | Ann Arbor | Michigan | 48105 | — |
| Local Institution - 0018 | Detroit | Michigan | 48202 | — |
| Local Institution - 0295 | Newark | New Jersey | 07103 | — |
| Local Institution - 0043 | Toledo | Ohio | 43623 | — |
| Local Institution - 0284 | Pittsburgh | Pennsylvania | 15212 | — |
| Local Institution - 0304 | Dallas | Texas | 75203 | — |
| Local Institution - 0202 | Houston | Texas | 77030 | — |
| Local Institution - 0046 | Lubbock | Texas | 79410 | — |
| Local Institution - 0172 | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 195 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04039607, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2026 · Synced Sep 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04039607 live on ClinicalTrials.gov.